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Abstract
Background: The aim of this study was to evaluate primary tumor heterogeneity in
patients with FDG-avid non-small cell lung cancer on PET/CT, with a view to optimising
prognostic information from the metabolic signature of the primary tumor.
Methods: A retrospective analysis of 94 [18F] FDG PET/CTs (56 M:38F) in patients with a
diagnosis of primary lung malignancy was performed. Data collected included patient
demographics, tumor size, maximum standardized uptake value (SUVmax), clinical
stage and tumor histology. Clinical follow up and survival data were obtained from the
available medical records. Tumor FDG spatial uptake heterogeneity was evaluated by
the lack of conformity of the FDG pattern within the tumor region of interest to
a simple 3-dimensional ellipsoidal form. A multivariate Cox regression analysis
was used to assess the added prognostic benefit of heterogeneity information
beyond radiological staging and other factors.
Results: Ninety four patients (mean age 67 years, range 36–85; 59.6% male)
were available for analysis. The clinical staging distribution had 25 Stage I, 14
Stage II, 38 Stage III and 17 Stage IV. Mean tumor FDG spatial uptake heterogeneity
was 25.87% with a range 2.78%–83.52%. Multivariate analysis found that heterogeneity,
clinical stage, SUVmax and gender were associated with survival. Greater FDG spatial
uptake heterogeneity is associated with significantly shorter survival (p = 0.0152). An
increase of 19.5% (1 standard deviation) in FDG spatial uptake heterogeneity, is
associated with a 43% increase in the risk of death.
Conclusion: Quantification of the FDG spatial uptake heterogeneity of lung tumors
has potential to add prognostic information to lung cancer staging beyond SUVmax
and clinical stage information.
Keywords: [18F] FDG PET/CT, NSCLC, Image analysis, Heterogeneity
Background
Lung cancer is the leading cause of cancer deaths worldwide (World Health Organisa-
tion, 2017). Net survival rates are poor in comparison to many other cancers, even for
early stage disease with technically successful surgical excision. National Institute for
Healthcare and Excellence (NICE) guidelines recommend all patients with a primary
lung cancer who are being treated with curative intent undergo [18F]
Fluoro-deoxy-glucose Positron Emission Tomography/ Computed Tomography (FDG
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PET/CT) as part of the staging process (National Institute for Health and Care Excel-
lence (NICE), 2011). PET/CT is a non-invasive imaging test commonly used for diag-
nosis and staging of malignant diseases. The most commonly used radiotracer is [18F]
FDG. It is now generally accepted that there is a strong correlation between [18F] FDG
uptake assessed with Positron Emission Tomography (PET) and number of viable can-
cer cells in many solid tumors (Wahl et al., 2009). Combined [18F] FDG-PET/ CT plays
a unique role in the assessment of many solid tumors due to its dual assessment of
metabolic function and tumor morphology rather than just morphology alone.
[18F] FDG PET/CT is used to help make the diagnosis of lung cancer, to help define
surgical versus non-surgical treatment candidates, and occasionally as part of follow-up
to assess for treatment response or recurrence. [18F] FDG-PET/CT has been shown to
be more accurate than conventional imaging in the detection of both nodal and distant
metastases in lung cancer, particularly in the more common non-small cell subtype
(Vansteenkiste & Dooms, 2007). Several studies have demonstrated the ability of [18F]
FDG-PET/CT to accurately predict favourable pathologic response to neoadjuvant
chemotherapy and radiotherapy (Hicks, 2009). Furthermore, there is accumulating data
to suggest that response to treatment on [18F] FDG-PET/CT is associated with im-
proved overall survival (Hicks, 2009).
Prognosis and treatment response variability are likely manifestations of the under-
lying tumor biology and heterogeneity in specific tumor biology characteristics. Tumor
heterogeneity refers to features at a cellular level (e.g. cellular proliferation and necro-
sis); to physiological changes (e.g. altered perfusion including haemorrhage and hypoxia
and tumor metabolism) as well as to molecular changes (e.g. EGFR mutations). These
factors can lead to different responses to therapy introducing significant challenges in
designing effective treatment strategies. The purpose of this study was to evaluate pri-
mary tumor metabolism heterogeneity reported with [18F] FDG PET/CT in the primary
tumor of patients with non-small cell lung cancer with a view to optimising the prog-
nostic information from the metabolic signature of the tumor.
Methods
A retrospective analysis of [18F] FDG PET/CTs in patients with a diagnosis of primary
non-small cell lung cancer was performed over a three year period (18/05/2012–18/05/
2015). Data collected included patient demographics, primary tumor PET/CT derived
maximum standardized uptake value (SUVmax) and clinical stage. Stage was reported
in standard categories as per International Association for the Study of Lung Cancer
(IASCLC) 7th edition (Stage I; II; IIIA; IIIB, IV). Our analysis combines Stages IIIA and
IIIB so that each patient falls into one of Stages I, II, III and IV. The study was designed
with overall patient survival as the main clinical end point of interest. Clinical follow
up and survival data were obtained from the available medical records. End points
chosen were death, date of last clinic appointment and date lost to follow up.
[18F] FDG PET/CT
Prior to treatment all patients underwent standard [18F] FDG PET/CT on a GE Discov-
ery VCT system as per our institutional protocol. The same protocol was used for all
patients, and all were performed on one machine in a single PET/CT centre. Patients
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were fasting for 6 h and a capillary glucose sample was checked prior to intravenous in-
jection of [18F] FDG (340–400 Megabecquerels) one hour before PET acquisition and
subsequent low dose non-contrast attenuation correction CT. Patients were positioned
supine with arms up and the scan range was from the lower orbital margin to the
upper third of the femora. CT was performed using free breathing and using standard
filter back projection reconstruction. 30 cm bed positions were obtained with 2–3 min
per bed position. PET/CT images were reconstructed and reviewed using a GE AW
workstation by a fellowship-trained radiologist. The PET reconstructed FDG images
are in units of activity (kBq/cc) are converted to standardized uptake units by scaling
the activity of the injected dose per unit weight of the patient (kBq/g). The primary
tumor for FDG spatial uptake was selected by a radiologist and a region of interest
(ROI) mapped around the entire tumor volume demonstrated by the [18F] FDG uptake
on the axial images. SUVmax was recorded as the maximum voxel-level SUV within
the ROI.
Heterogeneity analysis
An image analysis algorithm, previously validated in patients with sarcoma (Eary et al.,
2008), was used to quantify spatial heterogeneity of [18F] FDG SUV distribution. This
approach models the 3-D pattern of radiotracer uptake in a homogenous tumor mass
by a general ellipsoidally contoured structure, whose voxel intensity is greatest at the
centre and diminishes in a monotone fashion as one moves radially towards the periph-
ery of the mass. All voxels within the ROI are used for assessment. Thresholding was
not performed as voxels of lower intensity typically found at the tumor boundry would
by construction have only a very limited statistical influence on this model-based het-
erogeneity quantitation. FDG spatial uptake heterogeneity is assessed by the lack of
conformity of the observed uptake pattern to the best fitting ellipsoidally contoured
model. Heterogeneity (HET) is evaluated as the percent variance unexplained in the
ROI uptake values using the ellipsoidally contoured model. A comparative analysis pre-
sented by O’Sullivan et al. (2011), carried out on a sarcoma cohort including heteroge-
neous profiles, indicated that the nature of the nature of tumor delineation had only a
limited impact on the model-based heterogeneity assessment used in this analysis. By
construction, the latter is mainly driven by the uptake data located at the core of the
ROI, rather than the information located at its boundry (Eary et al., 2008). HET is
expressed as a percent (range 0–100), a low value indicating a more homogeneous
volumetric uptake distribution. Our heterogeneity analysis was performed on a
stand-alone workstation off-site using the R (R Core Team, 2016) statistical software.
Open-source R code for this analysis is available in (Wolsztynski & O'Sullivan, 2018).
Statistical analysis
Patient death was the primary endpoint; survival was defined as days from baseline
FDG PET scan to death. Clinical records were used to determine patient disease status
and prognostic factors. Univariate and multivariate analyses were performed using R (R
Core Team, 2016).
The question of interest is whether heterogeneity significantly contributes to a multi-
variable model of patient survival in non-small cell lung cancer which includes all
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known prognostic variables that were available in this dataset (age, gender, SUVmax,
and clinical stage were included in the analysis along with heterogeneity). Hazard ratios
were scaled so that they are shown as the hazard associated with a one standard devi-
ation increase in the comparison covariate.
Results
The PET/CT examinations of 98 patients with non-small cell lung cancer were evaluated.
Four studies were excluded as two demonstrated no [18F] FDG uptake, one study had no
follow-up data and one study was performed post-treatment (final n = 94). There were 56
male and 38 female patients with a median age of 69 years (range: 36–85 years-of-age).
Histological diagnoses included squamous cell carcinoma (n = 49), adenocarcinoma (n =
32), mixed non-small cell carcinoma and small cell carcinoma (n = 3), poorly differentiated
non-small cell carcinoma (n = 2), non-small cell lung carcinoma with neuroendocrine
morphology (n = 1), carcinoid (n = 1), pleomorphic carcinoma (n = 1), adenosquamous car-
cinoma (n = 1) and non-small cell carcinoma not otherwise specified (n = 4). There were 25
patients with clinical stage I disease, 14 patients with stage II disease, 38 patients with stage
III disease and 17 patients with stage IV disease. There were 58 deaths during the study
interval with a mean survival time of 332 days for those patients (range: 9–976 days).
Heterogeneity analysis was performed on 94 studies. The SUVmax range was from
0.91–26.2; the mean value was 9.95, median 8.91. The heterogeneity [HET] range was
2.78–83.53%; the mean value was 25.87%, median 20.19%.
Univariate analysis
Cox proportional hazard models were used to evaluate age, gender, clinical stage, SUV-
max and heterogeneity. Note clinical stage is partially based on radiological interpret-
ation of the PET information. Figure 1 presents Kaplan-Meier curves for the patient
cohort separated by clinical stage. Clinical stage and SUVmax were the strongest pre-
dictors of patient survival (see Table 1). Heterogeneity factor was not statistically sig-
nificant predictor of survival in univariate analysis (p = 0.082).
Multivariate analysis
Multivariate Cox proportional hazard models were also used to evaluate the relation-
ship between prognostic factors and time to death. Prognostic factors assessed included
gender, SUVmax, PET stage and heterogeneity. Clinical stage is the strongest predictor
of patient survival but all variables assessed, with the exception of age, showed signifi-
cance for survival prediction (Table 2, Figs. 2 and 3). Incorporation of FDG tumor
spatial uptake heterogeneity into the analysis significantly (p = 0.0152) improves a
model which included age, gender, clinical stage and SUVmax. This study finds that an
increase of 19.5% (1 SD) in heterogeneity is associated with 43% increase in the risk of
death, when all other variables remain fixed. A standalone increase of SUVmax of 6.11
(1 SD) is associated with a 36% increase in the risk of death.
Discussion
Accurate staging of non-small cell lung cancer is essential to plan appropriate manage-
ment and treatment strategies. NICE guidelines recommend that all patients with a
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primary lung cancer who are being treated with curative intent undergo [18F] FDG
PET/CT as part of the staging process (National Institute for Health and Care Excel-
lence (NICE), 2011). Studies have shown that [18F] FDG PET/CT improves sensitivity
in pre-operative staging of non-small cell lung cancer (Fischer et al., 2009) and our re-
sults have verified that stage is a strong predictor in multivariate prognostic models.
With the unique ability of PET/CT to provide both functional and anatomic informa-
tion we propose to add increased prognostic capability to clinical lung cancer staging
obtained from metabolic imaging of the primary tumor by evaluating FDG spatial up-
take heterogeneity in the tumor volume.
At present the metabolic assessment of the tumor is generally performed using the
measurement SUVmax. SUVmax has been confirmed to be a significant indicator of
tumor aggressiveness and prognosis in non small cell lung cancers (Berghmans et al.,
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Fig. 1 The Kaplan-Meier Survival curves for stage I-IV patients
Table 1 Univariate analysis
Hazard Ratio p-value R-sq C
Age 0.9710 0.8221 0.0005 0.5013
Sex 1.5306 0.1214 0.026 0.5544
SUVmax 1.7746 < 0.0001 0.163 0.6339
StageIIa 9.943 0.0006 0.3387 0.6783
StageIIIa 11.6324 0.0001 0.3387 0.6783
StageIVa 17.6745 < 0.0001 0.3387 0.6783
HET 1.2363 0.082 0.0293 0.6023
aClinical Stage for each of stages II-IV is relative to stage I
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2008). While the single measurement provided by the SUVmax is useful, any one value
is unlikely to capture all of the information that the 3-D PET scan may convey about
the tumor. Thus there is on-going interest to evaluate further measures which may
contribute to the prognostic value of the PET study. Texture-based radiomic measures
are being explored in various NSCLC settings where PET is used (Cook et al., 2013;
Tixier et al., 2014; Soussan et al., 2014; Orlhac et al., 2015).
Our approach adapts a technique developed and validated in the context of PET sar-
coma (Eary et al., 2008) to the NSCLC setting. Unlike texture-based radiomic ap-
proaches, our technique is based on a model of radiotracer uptake pattern.
Heterogeneity (HET) is assessed in terms of deviation from that model. The present
study shows that HET in a primary lung cancer tumor has the ability to add new
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Fig. 2 Kaplan-Meier survival curves for Stage II-IV patients with risk (above and below median) as defined
by the multivariable model - see Table 2. The black curves do not use Heterogeneity as a risk factor, the red
ones do. The p-value in the lower left evaluates (via a likelihood ratio analysis) the significance of the improved
separation between the low and high risk groups when the Heterogeneity information is included
Table 2 Multivariate analysis
Hazard Ratio p-value R-sq C
Age 1.0333 0.8303 0.4503 0.7531
Sex 1.9773 0.0281
SUVmax 1.3563 0.0329
Stage II 8.7036 0.0018
Stage III 10.3671 0.0002
Stage IV 20.2719 < 0.0001
HET 1.4287 0.0152
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additional prognostic information to the tumor staging process. Incorporation of HET
into a multivariate predictive model including gender, SUVmax and radiological stage
significantly enhances the understanding of survival characteristics for all patients.
Thus tumor heterogeneity measurements may provide further staging information that
could potentially influence how patients with NSCLC might be better managed. This
could be the focus for a further research study.
We hypothesize that the [18F] FDG heterogeneity reflects underlying biological het-
erogeneity. Biological heterogeneity may be a reflection of cell populations with differ-
ing growth rates, vascularity, necrosis and cavitation which, when seen histologically,
are features that may imply aggressive behavior. No single mechanism has been identi-
fied as a direct link between biologic heterogeneity and radiotracer heterogeneity (Galli-
vanone et al., 2017; Van Gomez Lopez et al., 2014) and it is likely a multifactorial
association. The morphological appearance of lung tumors on CT can often be
heterogenous, for example showing regions of contrast enhancement, necrosis, cavita-
tion or ground-glass opacification. Thus application of the above spatially focused het-
erogeneity measure may merit evaluation in the context of diagnostic CT information
obtained for NSCLC patients. In this context it could also be interesting to explore the
added benefit of [18F] FDG uptake heterogeneity, in relation to CT.
One of the limitations of our study is the small sample size which has not allowed for
assessment of heterogeneity as an independent prognostic factor however we would
propose that intratumoral heterogeneity assessment for tumor characterization would
complement tumor staging or grading, and its inclusion in a multivariate model that
Fig. 3 Illustration of the HET quantitation on two NSCLC studies, with high (top) and low (bottom)
heterogeneity. The corresponding scatterplots (right) illustrate the representation of the volumetric
tracer uptake (black dots) as a function of radial position within the ideal ellipsoid pattern, from core
(left hand side of the x-axis) to the volume boundary (right hand side of the x-axis). The HET variable
quantifies the lack of goodness-of-fit of the data-adaptive regression model (red) derived from this representation,
thus assessing how well the idealized ellipsoidal pattern describes the observed uptake data
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includes staging information serves to evaluate the additional prognostic potential it
may provide. Further research is required to evaluate the influence of HET as a prog-
nostic factor in different stages of lung cancers, with a larger sample size.
Conclusion
FDG spatial uptake heterogeneity within a primary non-small cell lung cancer tumor
may be associated with a poorer prognosis and incorporation of this tumor characteris-
tic adds prognostic significance to a model including clinical stage, gender and tumor
SUVmax. Further studies are required to demonstrate if lung tumor FDG heterogeneity
measurement could provide valuable prognostic information which could be used as
part of the decision making process for treatment planning. In conclusion, the use of
PET/CT in this way has potential to add prognostic information beyond that of trad-
itional imaging evaluation, by quantification of the spatial heterogeneity of [18F] FDG
uptake in the primary tumor.
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